EMA CHMP Recommends Gazyva/Gazyvaro as Add-on Therapy for Adult SLE
The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended on Tuesday the approval of obinutuzumab as an add-on therapy for adults with moderate to severe systemic lupus erythematosus (SLE).
This regulatory milestone for the drug, marketed as Gazyva or Gazyvaro, follows positive results from the Phase III ALLEGORY trial, which demonstrated significant reductions in disease activity for patients who remained symptomatic despite receiving standard care.
Key Clinical Takeaways:
- Patients receiving obinutuzumab showed a 76.7% response rate at 52 weeks compared to 53.5% for those on placebo plus standard therapy.
- The therapy is a type II anti-CD20 monoclonal antibody designed to induce direct B-cell depletion, a mechanism distinct from earlier anti-CD20 treatments.
- The European Commission is expected to issue a final marketing authorization decision in the near future, following the positive CHMP opinion.
ALLEGORY Trial Outcomes in Lupus Management
The recommendation by the CHMP relies on data from the ALLEGORY study, a randomized, double-blind, placebo-controlled trial involving approximately 300 adults. According to the study results published in the New England Journal of Medicine, the primary endpoint was the proportion of patients achieving an SLE Responder Index (SRI-4) score at 52 weeks.
The trial reported a 23.1% adjusted difference in SRI-4 response rates between the treatment and control groups, with a p-value of less than 0.001, as reported by Farmacosalud.
Beyond the primary endpoint, the data indicated that obinutuzumab outperformed placebo across secondary measures, including sustained glucocorticoid reduction and the British Isles Lupus Assessment Group (BICLA) composite score, according to Farmacosalud.
Farmacosalud said that patients treated with the biologic also achieved higher rates of remission, defined by the DORIS criteria, at 33.8% versus 13.8% for the placebo group. These findings suggest a potential shift in the standard of care for patients with persistent, active disease.

Obinutuzumab Targets CD20 to Deplete Pathogenic B-Cells
Obinutuzumab is a humanized monoclonal antibody engineered with a glycoengineered Fc region to enhance antibody-dependent cellular cytotoxicity. By targeting the CD20 protein on the surface of B-cells, the therapy facilitates the depletion of cells implicated in the pathogenesis of autoimmune conditions. MarketScreener España reported that this mechanism is intended to address the underlying inflammatory processes that drive recurrent flares and progressive organ damage in SLE patients.
Systemic lupus erythematosus affects approximately three million people globally, with up to 270,000 individuals living with the condition in Europe. The disease is characterized by chronic inflammation that can involve multiple organ systems, particularly the kidneys, skin, and joints. Because of the variability in clinical presentation, patients frequently experience a diagnostic delay of three to five years, during which time cumulative organ damage may occur, according to Farmacosalud.
The regulatory progress of obinutuzumab in SLE aligns with its established use in other immune-mediated conditions. The drug is currently approved for active lupus nephritis in more than 65 countries and for idiopathic nephrotic syndrome in the United States, as noted by infosalus.
Roche, the developer of the therapy, is also investigating other candidates, such as the CD20xCD3 bispecific antibody mosunetuzumab, for use in SLE patients with or without active kidney involvement.

“Many people with systemic lupus erythematosus experience recurrent flares, progressive organ damage, and chronic steroid dependency,” said Dr. Levi Garraway, chief medical officer and head of Global Product Development at Roche, in a statement reported by IM Médico.
The timing of the final decision by the European Commission remains pending. Once authorized, the integration of obinutuzumab into regional formularies will depend on individual member state policies regarding reimbursement and accessibility.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.